ASCO 2023 | Rational for neoadjuvant ICI-based therapy in oncogene-driven resectable NSCLC

Samuel Rosner, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the rationale behind investigating neoadjuvant immune checkpoint inhibition (ICI)–based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC). Dr Rosner highlights that certain oncogene drivers in metastatic NSCLC have shown less favorable responses to immune checkpoint blockade, necessitating a personalized approach to first-line therapy and biomarker testing. The question arises whether these same paradigms should be applied in the neoadjuvant setting to refine and personalize therapy for patients with oncogene-driven NSCLC. This emphasizes the need for further research and analysis to determine the optimal treatment strategies in this context. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.